Pharmacogenetics of drug-induced arrhythmias

Expert Review of Clinical Pharmacology

Volumn 1, Issue 1, 2008, Pages 93-104

  Abbot, Geoffrey W ^a   Roepke, Torsten K ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANKYRIN; ANTIANGINA PECTORIS AGENT; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CAVEOLIN 3; CLARITHROMYCIN; DOFETILIDE; ION CHANNEL; NEUROLEPTIC AGENT; OPIATE AGONIST; OXATOMIDE; PENTAMIDINE; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KCNE1; POTASSIUM CHANNEL KCNE2; POTASSIUM CHANNEL KCNQ1; POTASSIUM CHANNEL MINK; POTASSIUM CHANNEL MIRP1; PROCAINAMIDE; PROTEINASE INHIBITOR; QUINIDINE; SODIUM CHANNEL SCN5A; SOTALOL; SULFAMETHOXAZOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLTAGE GATED POTASSIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL;

ACTION POTENTIAL; BIOGENESIS; BRADYCARDIA; CELL ACTIVITY; CHANNELOPATHY; DEFIBRILLATION; DRUG MECHANISM; ENVIRONMENTAL FACTOR; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART MUSCLE CELL; HEREDITY; HUMAN; HYPOKALEMIA; LEISHMANIASIS; LEUKEMIA; LONG QT SYNDROME; NONHUMAN; ONTOGENY; PHARMACOGENETICS; PNEUMOCYSTIS PNEUMONIA; REVIEW; RISK FACTOR; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; SHORT QT SYNDROME; TORSADE DES POINTES; TRYPANOSOMIASIS;

EID: 38349063022     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/17512433.1.1.93     Document Type: Review

References (129)

1. Stuhmer W, Conti F, Suzuki et al. Structural parts involved in activation and inactivation of the sodium channel. Nature 339(6226), 597-603 (1989).
2. Lehmann-Horn F, Jurkat-Rott K. Voltagegated ion channels and hereditary disease. Physiol. Rev. 79(4), 1317-1372 (1999).
3. + channel diversity in the mammalian myocardium. J. Physiol. (Lond.) 525(Pt 2), 285-298 (2000).
4. Roden DM. Pharmacogenetics and drug induced arrhythmias. Cardiovasc. Res. 50(2), 224-231 (2001).
5. Anantharam A, Markowitz SM, Abbott GW. Pharmacogenetic considerations in diseases of cardiac ion channels. J. Pharmacol. Exp. Ther. 307(3), 831-838 (2003).
6. Sanguinetti MC. Long QT syndrome: ionic basis and arrhythmia mechanism in long QT syndrome type 1. J. Cardiovasc. Electrophysiol. 11(6), 710-712 (2000).
7. January CT, Gong Q, Zhou Z. Long QT syndrome: cellular basis and arrhythmia me13chanism in LQT2. J. Cardiovasc. Electrophysiol. 11(12), 1413-1418 (2000).
8. Roden DM. Early after-depolarizations and torsade de pointes: implications for the control of cardiac arrhythmias by prolonging repolarization. Eur. Heart J. 14(Suppl. H), 56-61 (1993).
9. Balser JR. The cardiac sodium channel: gating function and molecular pharmacology. J. Mol. Cell Cardiol. 33(4), 599-613 (2001).
10. Bellocq C, van Ginneken AC, Bezzjna CR et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation 109(20), 2394-2397 (2004).
11. Gaita F, Giustetto C, Bianchi F et al. Short QT syndrome: a familial cause of sudden death. Circulation 108(8), 965-970 (2003).
12. Hong K, Bjerregaard P, Gussak I, Brugada R. Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. J. Cardiovasc. Electrophysiol. 16(4), 394-396 (2005).
13. Priori SG, Pandit SV, Rivolta I et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ. Res. 96(7), 800-807 (2005).
14. Brugada J, Brugada P, Brugada R. The syndrome of right bundle branch block ST segment elevation in V1 to V3 and sudden death - the Brugada syndrome. Europace 1(3), 156-166 (1999).
15. Yang P, Kanki H, Drolet B et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 105(16), 1943-1948 (2002).
16. Smith PL, Baukrowitz T, Yellen G. The inward rectification mechanism of the HERG cardiac potassium channel. Nature 379(6568), 833-836 (1996).
17. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80(5), 795-803 (1995).
18. Splawski I, Shen J, Timothy KW et al. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 102(10), 1178-1185 (2000).
19. Eckhardt LL, Rajamani S, January CT. Protein trafficking abnormalities: a new mechanism in drug-induced long QT syndrome. Br. J. Pharmacol. 145(1), 3-4 (2005).
20. McCrossan ZA, Abbott GW. The MinK-related peptides. Neuropharmacology 47(6), 787-821 (2004).
21. Abbott GW, Sesti F, Splawski I et al. MiRP1 forms IKr potassium channels with HERG and Is associated with cardiac arrhythmia. Cell 97(2), 175-187 (1999).
22. Jiang M, Zhang M, Tang DG et al. KCNE2 protein is expressed in ventricles of different species, and changes in its expression contribute to electrical remodeling in diseased hearts. Circulation 109(14), 1783-1788 (2004).
23. Chen YH, Xu SJ, Bendahhou S et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 299(5604), 251-254 (2003).
24. Pourrier M, Zicha S, Ehrlich J, Han W, Nattel S. Canine ventricular KCNE2 expression resides predominantly in purkinje fibers. Circ. Res. 93, 189-191 (2003).
25. Mazhari R, Greenstein JL, Winslow RL, Marban E, Nuss HB. Molecular interactions between two long-QT syndrome gene products, HERG and KCNE2, rationalized by in vitro and in silico analysis. Circ. Res. 89(1), 33-38 (2001).
26. Burton DY, Song C, Fishbein I et al. The incorporation of an ion channel gene mutation associated with the long QT syndrome (Q9E-hMiRP1) in a plasmid vector for site-specific arrhythmia gene therapy: in vitro and in vivo feasibility studies. Hum. Gene Ther. 14(9), 907-922 (2003).
27. Cui J, Kagan A, Qin D, Mathew J, Melman YF, McDonald TV. Analysis of the cyclic nucleotide binding domain of the HERG potassium channel and interactions with KCNE2. J. Biol Chem. 276(20), 17244-17251 (2001).
28. + channel by dual pathways. Curr. Biol. 10(11), 671-674 (2000).
29. Friederich P, Solth A, Schillemeit S, Isbrandt D. Local anaesthetic sensitivities of cloned HERG channels from human heart: comparison with HERG/MiRP1 and HERG/MiRP1 T8A. Br. J. Anaesth. 92(1), 93-101 (2004).
30. + channel gating: a mechanism for pro-arrhythmia in long QT syndrome type 6. J. Physiol. (Lond.) 551(1), 253-262 (2003).
31. Numaguchi H, Mullins FM, Johnson JP et al. Probing the interaction between inactivation gating and Dd-sotalol block of HERG. Circ. Res. 87(11), 1012-1018 (2000).
32. + currents by thyrotropin-releasing hormone in anterior pituitary cells via the native signal cascade. J. Physiol. (Lond.) 532(Pt 1), 143-163 (2001).
33. Weerapura M, Nattel S, Chartier D, Caballero R, Hebert TE. A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link? J. Physiol. (Lond.) 540(Pt 1), 15-27 (2002).
34. Zhang M, Jiang M, Tseng GN. MinK-related peptide 1 associates with Kv4.2 and modulates its gating function: potential role as β subunit of cardiac transient outward channel? Circ. Res. 88(10), 3012-1019 (2001).
35. Isbrandt D, Friederich P, Solth A et al. Identification and functional characterization of a novel KCNE2 (MiRP1) mutation that alters HERG channel kinetics. J. Mol. Med. 80(8), 524-532 (2002).
36. Chun KR, Koenen M, Katus HA, Zehelein J. Expression of the IKr components KCNH2 (rERG) and KCNE2 (rMiRP1) during late rat heart development. Exp. Mol. Med. 36(4), 367-371 (2004).
37. Decher N, Bundis F, Vajna R, Steinmeyer K. KCNE2 modulates current amplitudes and activation kinetics of HCN4: influence of KCNE family members on HCN4 currents. Pflugers Arch. 446(6), 633-640 (2003).
38. Heitzmann D, Grahammer F, von Hahn T et al. Heteromeric KCNE2/ KCNQ1 potassium channels in the luminal membrane of gastric parietal cells. J. Physiol. (Lond.) 561(Pt 2), 547-557 (2004).
39. Lewis A, McCrossan ZA, Abbott GW. MinK, MiRP1 and MiRP2 diversify Kv3.1 and Kv3.2 potassium channel gating. J. Biol. Chem. 279, 2884-2892 (2004).
40. Qu J, Kryukova Y, Potapova IA et al. MiRP1 modulates HCN2 channel expression and gating in cardiac myocytes. J. Biol. Chem. 279(42), 43497-43502 (2004).
41. Tinel N, Diochot S, Borsotto M, Lazdunski M, Barhanin J. KCNE2 confers background current characteristics to the cardiac KCNQ1 potassium channel. EMBO J. 19(23), 6326-6330 (2000).
42. Tinel N, Diochot S, Lauritzen I, Barhanin J, Lazdunski M, Borsotto M. M-type KCNQ2-KCNQ3 potassium channels are modulated by the KCNE2 subunit. FEBS Lett. 480(2-3), 137-141 (2000).
43. Yang Y, Xia M, Jin Q et al. Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation. Am. J. Hum. Genet. 75(5), 899-905 (2004).
44. Yu H, Wu J, Potapova IJ et al. MinK-related peptide 1: A β subunit for the HCN ion channel subunit family enhances expression and speeds activation. Circ. Res. 88(12), E84-E87 (2001).
45. Stein KM, Haronian H, Mensah GA, Acosta A, Jacobs J, Kligfield P. Ventricular tachycardia and torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Am. J. Cardiol. 66(10), 888-889 (1990).
46. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC. A structural basis for drug-induced long QT syndrome. Proc. Natl Acad. Sci. USA 97(22), 12329-12333 (2000).
47. Kass RS, Cabo C. Channel structure and drug-induced cardiac arrhythmias. Proc. Natl Acad. Sci. USA 97(22), 11683-11684 (2000).
48. Anson BD, Weaver JG, Ackerman MJ et al. Blockade of HERG channels by HIV protease inhibitors. Lancet 365(9460), 682-686 (2005).
49. De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf. 25(4), 263-286 (2002).
50. Picard S, Lacroix P. QT interval prolongation and cardiac risk assessment for novel drugs. Curr. Opin. Investig. Drugs 4(3), 303-308 (2003).
51. Rampe D, Roy ML, Dennis A, Brown AM. A mechanism for the proarrhythmic effects of cisapride (propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett. 417(1), 28-32 (1997).
52. Shah RR. Drug-induced QT interval prolongation - regulatory guidance and perspectives on hERG channel studies. Novartis Found Symp. 266, 251-285 (2005).
53. Volberg WA, Koci BJ, Su W, Lin J, Zhou J. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J. Pharmacol. Exp. Ther. 302(1), 320-327 (2002).
54. kr: model systems and relevance to human arrhythmias. J. Cardiovasc. Pharmacol. 38(5), 737-744 (2001).
55. + channel using docking and molecular dynamics methods. FEBS Lett. 579(13), 2939-2944 (2005).
56. + channel and its structural implications. Nature 403(6767), 321-325 (2000).
57. Labro AJ, Raes AL, Bellens I, Ottschytsch N, Snyders DJ. Gating of shaker-type channels requires the flexibility of S6 caused by prolines. J. Biol. Chem. 278(50), 50724-50731 (2003).
58. Shrivastava IH, Capener CE, Forrest LR, Sansom MS. Structure and dynamics of K channel pore-lining helices: a comparative simulation study. Biophys. J. 78(1), 79-92 (2000).
59. Tieleman DP, Shrivastava IH, Ulmschneider MR, Sansom MS. Proline-induced hinges in transmembrane helices: possible roles in ion channel gating. Proteins 44(2), 63-72 (2001).
60. Mitcheson JS, Chen J, Sanguinetti MC. Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate. J. Gen. Physiol. 115(3), 229-240 (2000).
61. Trudeau MC, Warmke JW, Ganetzky B, Robertson GA. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 269(5220), 92-95 (1995).
62. Barbey JT, Soignet S. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann. Intern. Med. 135(9), 842-843 (2001).
63. Ohnishi K, Yoshida H, Shigeno K et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann. Intern. Med. 133(11), 881-885 (2000).
64. Soignet SL, Frankel SR, Douer D et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J. Clin. Oncol. 19(18), 3852-3860 (2001).
65. Cordes JS, Sun Z, Lloyd DB et al. Pentamidine reduces hERG expression to prolong the QT interval. Br. J. Pharmacol. 145, 15-23 (2005).
66. Kuryshev YA, Ficker E, Wang L et al. Pentamidine-induced long QT syndrome and block of hERG trafficking. J. Pharmacol. Exp. Ther. 312(1), 316-323 (2005).
67. Stein KM, Fenton C, Lehany AM, Okm PM, Kligfield P. Incidence of QT interval prolongation during pentamidine therapy of Pneumocystis carinii pneumonia. Am. J. Cardiol. 68(10), 1091-1094 (1991).
68. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. J. Am. Med. Assoc. 270, 2590-2597 (1993).
69. Kr potassium channel. Cell 81(2), 299-307 (1995).
70. Berthet M, Denjoy I, Donger C et al. C-terminal HERG mutations: the role of hypokalemia and a KCNQ1 associated mutation in cardiac event occurrence. Circulation 99(11), 1464-1470 (1999).
71. Sean F, Abbott GW Wei J et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc. Natl Acad. Sci. USA 97(19), 10613-10618 (2000).
72. Sun Z, Milos PM, Thompson JF et al. Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced torsades de pointes. J. Mol. Cell. Cardiol. 37(5), 1031-1039 (2004).
73. Hayashi K, Shimizu M, Ino H et al. Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG. Clin. Sci. 107(2), 175-182 (2004).
74. Bellocq C, Wilders R, Schott JJ et al. A common antitussive drug, clobutinol, precipitates the long QT syndrome 2. Mol. Pharmacol. 66(5), 1093-1102 (2004).
75. + channels. Circ. Res. 82(3), 386-395 (1998).
76. Kiehn J, Lacerda AE, Wible B, Brown AM. Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide. Circulation 94(10), 2572-2579 (1996).
77. Ackerman MJ, Tester DJ, Jones GS, Will ML, Burrow CR, Curran ME. Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. Mayo Clin. Proc. 78(12), 1479-1487 (2003).
78. Park KH, Kwok SM, Sharon C, Berga R, Sesti F. N-glycosylation-dependent block is a novel mechanism for drug-induced cardiac arrhythmia. FASEB J. 17(15), 2308-2309 (2003).
79. vLQT1 and lsK (minK) proteins associate to form the I(Ks) cardiac potassium current. Nature 384(6604), 78-80 (1996).
80. Ks potassium channel. Nature 384(6604), 80-83 (1996).
81. Neyroud N, Tesson F, Denjoy I et al. A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome. Nat. Genet. 15(2), 186-189 (1997).
82. Wang Q, Curran ME, Splawski I et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat. Genet. 12(1), 17-23 (1996).
83. Ks function. Nat. Genet. 17(3), 338-340 (1997).
84. Ks and KvLQT1: mutation in either of the two subunits of the slow component of the delayed rectifier potassium channel can cause Jervell and Lange-Nielsen syndrome. Hum. Mol. Genet. 6(12), 2179-2185 (1997).
85. Rivas A, Francis HW. Inner ear abnormalities in a Kcnq1 (Kvlqt1) knockout mouse: a model of Jervell and Lange-Nielsen syndrome. Otol. Neurotol. 26(3), 415-424 (2005).
86. Casimiro MC, Knollmann BC, Ebert SN et al. Targeted disruption of the Kcnq1 gene produces a mouse model of Jervell and Lange-Nielsen Syndrome. Proc. Natl Acad. Sci. USA 98(5), 2526-2531 (2001).
87. Chorbachi R, Graham JM, Ford J, Raine CH. Cochlear implantation in Jervell and Lange-Nielsen syndrome. Int. J. Pediatr. Otorhinolaryngol. 66(3), 213-221 (2002).
88. + cycling and its regulation in the cochlea and the vestibular labyrinth. Audiol Neurootol. 7(4), 199-205 (2002).
89. Kr. Nature 388(6639), 289-292 (1997).
90. + current. Circ. Res. 77(6), 1246-1253 (1995).
91. + currents by an antisense oligodeoxynucleotide against IsK (minK) and over-expression of IsK mutant D77N in neonatal mouse hearts. Pflugers Arch. 442(3), 329-335 (2001).
92. Finley MR, Li Y, Hua F et al. Expression and coassociation of ERG1, KCNQ1, and KCNE1 potassium channel proteins in horse heart. Am. J. Physiol. Heart Circ. Physiol. 283(1), H126-H138 (2002).
93. Paulussen AD, Gilissen RA, Armstrong M et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J. Mol. Med. 82(3), 182-188 (2004).
94. Silva J, Rudy Y. Subunit interaction determines IKs participation in cardiac repolarization and repolarization reserve. Circulation 112(10), 1384-13891 (2005).
95. Splawski I, Timothy KW, Tateyama M et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 297, 1333-1336 (2002).
96. Plant LD, Bowers PN, Liu Q et al. A common cardiac sodium channel variant associated with sudden infant death in African Americans, SCN5A S1103Y. J. Clin. Invest. 116(2), 430-435 (2006).
97. Paul AA, Witchel HJ, Hancox JC. Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. Br. J. Pharmacol. 136(5), 717-729 (2002).
98. Brugada R, Brugada I, Antzelevitch C et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 101(5), 510-515 (2000).
99. Priori SG, Napolitano C, Schwartz PJ, Bloise R, Crotti L, Ronchetti E. The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge. Circulation 102(9), 945-947 (2000).
100. + channels: evidence from experiments with neutral and quaternary flecainide analogues. J. Gen. Physiol. 121(3), 199-214 (2003).
101. Zhu Y, Kyle JW, Lee PJ. Flecainide sensitivity of a Na channel long QT mutation shows an open-channel blocking mechanism for use-dependent block. Am. J. Physiol. Heart Circ. Physiol. 291(1), H29-H37 (2006).
102. Mohler PJ, Schott JJ, Gramolini AO et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 421(6923), 634-639 (2003).
103. Mohler PJ, Splawski I, Napolitano C et al. A cardiac arrhythmia syndrome caused by loss of ankyrin-B function. Proc. Natl Acad. Sci. USA 101(24), 9137-9142 (2004).
104. Mohler PJ, Le Scouarnec S, Denjoy I et al. Defining the cellular phenotype of 'ankyrin-B syndrome' variants: human ANK2 variants associated with clinical phenotypes display a spectrum of activities in cardiomyocytes. Circulation 115(4), 432-441 (2007).
105. Vatta M, Ackerman MJ, Ye B et al. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation 114(20), 2104-2112 (2006).
106. v1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 119(1), 19-31 (2004).
107. + channel. Mol. Pharmacol. 67(3), 827-836 (2005).
108. Zhou J, Augelli-Szafran CE, Bradley JA et al. Novel potent hERG potassium channel enhancers and their in vitro antiarrhythmic activity. Mol. Pharmacol. 68(3), 876-884 (2005).
109. Zhou J, Augelli-Szafran CE, Bradley JA et al. Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity. Mol. Pharmacol. 68(3), 876-884 (2005).
110. Zhou Z, Gong Q, January CT Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. Pharmacological and temperature effects. J. Biol. Chem. 274(44), 31123-31126 (1999).
111. + channel long-QT2 mutations: human ether-a-go-go-related gene rescue without block. Circulation 105(24), 2830-2835 (2002).
112. Delisle BP, Anderson CL, Balijepalli RC, Anson BD, Kamp TJ, January CT. Thapsigargin selectively rescues the trafficking defective LQT2 channels G601S and F805C. J. Biol. Chem. 278(37), 35749-35754 (2003).
113. Ficker E, Thomas D, Viswanathan PC et al. Novel characteristics of a misprocessed mutant HERG channel linked to hereditary long QT syndrome. Am. J. Physiol. Heart Circ. Physiol. 279(4), H1748-H1756 (2000).
114. Ficker E, Obejero-Paz CA, Zhao S, Brown AM. The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations. J. Biol. Chem. 277(7), 4989-4998 (2002).
115. + currents in rat atrial myocytes. J. Physiol. (Lond.) 517(Pt 2), 407-420 (1999).
116. Dixon JE, McKinnon D. Quantitative analysis of potassium channel mRNA expression in atrial and ventricular muscle of rats. Circ. Res. 75(2), 252-260 (1994).
117. + channel in the sinoatrial node. J. Histochem. Cytochem. 48(6), 769-780 (2000).
118. + current in canine atrial myocytes. Circ. Res. 93(8), 744-751 (2003).
119. Brendel J, Peukert S. Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias. Curr. Med. Chem. Cardiovasc. Hematol. Agents 1(3), 273-287 (2003).
120. Pirard B, Brendel J, Peukert S. The discovery of Kv1.5 blockers as a case study for the application of virtual screening approaches. J. Chem. Inf. Model. 45(2), 477-485 (2005).
121. Gogelein H, Brendel J, Steinmeyer K et al. Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels. Naunyn Schmiedebergs Arch. Pharmacol. 370(3), 183-192 (2004).
122. Schotten U, Van Wagoner DR, Hanrath P, Gogelein H, Allessie M. The Ito/ IKur blocker AVE0118 fully restores atrial contractility after cardioversion of atrial fibrillation. Gottingen, Germany (2005).
123. + channel gene KCNA5. Clin. Pharmacol. Ther. 77(3), 138-144 (2005).
124. Seebohm G, Pusch M, Chen J, Sanguinetti MC. Pharmacological activation of normal and arrhythmia associated mutant KCNQ1 potassium channels. Circ. Res. 93(10), 941-947 (2003).
125. Perlstein I, Burton DY, Ryan K et al. Posttranslational control of a cardiac ion channel transgene in vivo: clarithromycin-hMiRP1-Q9E interactions. Hum. Gene Ther. 16(7), 906-910 (2005).
126. Donger C, Denjoy I, Berthet M et al. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation 96(9), 2778-2781 (1997).
127. Napolitano C, Schwartz PJ, Brown AM et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arthythmias. J. Cardiovasc. ELectrophysiol. 11(6), 691-696 (2000).
128. Guo J, Massaeli H, Li W et al. Identification of IKr and its trafficking disruption induced by probucol in cultured neonatal rat cardiomyocytes. J. Pharmacol. Exp. Ther. 321(3), 911-920 (2007).
129. Makita N, Horie M, Nakamura T et al. Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation. Circulation 106(10), 1269-1274 (2002).